Salute e Benessere

Upcoming 89th CMEF in Shanghai to Showcase Innovative Technological Advancements…

A multitude of medical enterprises around the world will gather, showcasing the innovative applications of AI technology in the healthcare field. A spotlight will be shined on the advancements made in hospital operating room equipment, including an array of upgrades and innovations. Notably, intelligent surgical robots have also made significant strides by utilizing AI algorithms, offering increased precision and completeness in surgical procedures, which help assist doctors in completing…
PR Newswire
11/03/2024

Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care

Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group said, "For four decades, Apollo Hospitals has pioneered healthcare, advancing exceptional care. We pledge to democratize technology, making it accessible to all citizens and global communities, elevating standards of brain tumor treatment and ensuring better quality of life. ZAP-X strengthens the battle against Non-Communicable Diseases, especially cancers with superior outcomes." Dr Prathap Chandra Reddy, Founder…
PR Newswire
11/03/2024

SAFE - Bond financing agreement in a minimum amount of €850,000 to support the…

Bond financing agreement in a minimum amount of €850,000to support the Group's turnaround strategyEragny-sur-Oise–France – March 11, 2024, 8.00 a.m.Safe SA (the“Company” ) announces that it has arranged flexible bond financing with the Global Corporate Finance Opportunities 20 (GCFO 20) fund, a member of the Alpha Blue Ocean (ABO) group, through the issuance of warrants giving access to bonds convertible or exchangeable into new and/or existing shares with warrants attached in...
Nasdaq GlobeNewswire
11/03/2024

ONWARD® Medical Accepted to New US FDA TAP Program for Development of its…

The Company is one of the first brain-computer interface entrants accepted into this program, intended to optimize the commercialization pathway for breakthrough medical technology This acceptance follows ONWARD Medical's announcement last week that its investigational ARC-BCI System was awarded FDA Breakthrough Device Designation (BDD), a requirement for TAP consideration. ONWARD Medical is only the second BCI company to be accepted into the program. TAP provides ONWARD Medical with...
Nasdaq GlobeNewswire
11/03/2024

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and…

Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment.David Veitch,...
Nasdaq GlobeNewswire
11/03/2024

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American…

Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections,today announces that the Company's voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of the Company. The Company will...
Nasdaq GlobeNewswire
11/03/2024

PolTREG receives CGMP certification to produce cell therapies at its…

Gdańsk, Poland – 11 March 2024– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has received CGMP certification from Poland's Chief Pharmaceutical Inspectorate, allowing it to produce cellular therapies (Advanced Therapy Medicinal Products – ATMP) in its own site. The certification also enables it to seek permission from Poland's Office for Registration of Medicinal...
Nasdaq GlobeNewswire
11/03/2024

Press Release: New Phase 2b results for amlitelimab support potential for…

New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and symptoms with amlitelimab for 28 weeks The safety profile for patients dosed to 52 weeks was consistent with amlitelimab 24 weeks data showing it to be well-tolerated with no new safety concerns identifiedDurability of response supports quarterly dosing currently being investigated in Phase...
Nasdaq GlobeNewswire
11/03/2024

MoonLake announces significant improvements with Nanobody® sonelokimab over 24…

MoonLake announces significant improvements with Nanobody ®sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayPositive 24-week data from the ARGO trial of sonelokimab in PsA:Significant improvements observed across all key outcomes, including approximately 60% of patients treated with sonelokimab achieving an ACR50 response at week 24Unprecedented multi-domain responses across joints, skin and other domains, including...
Nasdaq GlobeNewswire
10/03/2024

Ultimovacs ASA: Mandatory notification of trades by primary insider

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachment 20240309 - Ultimovacs Notification of trade - PDMR form
Nasdaq GlobeNewswire
09/03/2024

Ultimovacs ASA: Mandatory notification of trades by primary insider

Oslo, 8 March 2024:CGS Holding AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per share. Following these transactions, CGS Holding AS holds 0 shares in Ultimovacs ASA. Helene Sundt AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of NOK 7.2507 per...
Nasdaq GlobeNewswire
08/03/2024

Inside information: Bioretec's European market authorization for RemeOs trauma…

Further enquiries Further enquiries Timo Lehtonen, CEO, +358 50 433 8493Johanna Salko, CFO, +358 40 754 8172 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture...
PR Newswire
08/03/2024

Wegovy® approved in the US for cardiovascular risk reduction in people with…

Bagsværd, Denmark, 8 March 2024– Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ®based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD). The approval is...
Nasdaq GlobeNewswire
08/03/2024

EssilorLuxottica: 2023 Universal Registration Document filed

2023 Universal Registration Document filedCharenton-le-Pont, France (March 8, 2024 – 6:30 pm)– EssilorLuxottica announces the availability of its 2023 Universal Registration Document, in accordance with applicable regulation. The French version of this document, prepared in ESEF format (European Single Electronic Format), was filed with theAutorité des Marchés Financiers(AMF, the French market regulator) on March 8, 2024 under the reference D.24-0087. The Universal Registration...
Nasdaq GlobeNewswire
08/03/2024

Melanoma risk prediction of nodal metastasis and long-term survival outcome by…

The analysis unveiled Merlin test's pivotal role in effectively stratifying CM patients based on their risk of disease recurrence. The poster will be presented on March 9, 8:50AM at AAD (San Diego Convention Center, Upper Level, Sails Pavilion, Poster Center 20). The analysis unveiled Merlin test's pivotal role in effectively stratifying CM patients based on their risk of disease recurrence. The poster will be presented onMarch 9,8:50AMat AAD ( San DiegoConvention Center, Upper Level,...
PR Newswire
08/03/2024

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 13 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 8, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
08/03/2024

Medical Waste Management Market Worth $12.2 billion | MarketsandMarkets™

Browse in-depth TOC on "Medical Waste Management Market" Browse in-depth TOC on "Medical Waste Management Market" 235 - Tables 39 - Figures 231 - Pages Medical Waste Management Market Scope: In 2022, collection, transport and storage services segment held for the largest share of medical waste management market, by services segment. The medical waste management market is segmented into collection, transport and storage services, treatment & disposal services and...
PR Newswire
08/03/2024

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and…

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and...
Nasdaq GlobeNewswire
08/03/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 08032024_trading_in_shares_LRA
Nasdaq GlobeNewswire
08/03/2024

Colombia leaded several topics at the WTO Ministerial Conference in Abu Dhabi

This extension means that none of the WTO's 164 member countries can make complaints against those who uphold measures defending their citizens' wellbeing in terms of rights granted in the field of intellectual property, even if it reduces benefits for the complaining country. This extension means that none of the WTO's 164 member countries can make complaints against those who uphold measures defending their citizens' wellbeing in terms of rights granted in the field of intellectual…
PR Newswire
08/03/2024

Anti-inflammatory Tea Market to Reach $3,592.4 Million, Globally, by 2032 at…

Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/A321985 Download Free Sample Report:https://www.alliedmarketresearch.com/request-sample/A321985 Prime determinants of growth The growth of the anti-inflammatory tea market is primarily driven by increased awareness of natural remedies and herbal supplements, as consumers increasingly seek alternatives to pharmaceuticals. This trend is further fuelled by the rise in incidence of chronic conditions such...
PR Newswire
08/03/2024

Vatika Naturals Inspires Inclusivity in Workplace with the #RootForMe Campaign

#ROOTFORME is a digital campaign to mark IWD2024 addressing intersectionality at workplace which affects women of colour, compounded by race, ethnicity, religion and several other issues which can pose as a major roadblock for career advancement for a lot of our target segment and make them susceptible to workplace harassment and stereotyping. #ROOTFORME is a digital campaign to mark IWD2024 addressing intersectionality at workplace which affects women of colour, compounded by race,...
PR Newswire
08/03/2024

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order. The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company. The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease…
PR Newswire
08/03/2024

Sectra's nine-month interim report 2023/2024: The industry's most satisfied…

Nine-month period (May 2023–January 2024) in figures Nine-month period (May 2023–January 2024) in figures Comments from Torbjörn Kronander, President and CEO of Sectra AB:"A sustainable future is about making our customers successful. I can't repeat this enough. To succeed we must have satisfied customers, which in turn requires that we have satisfied employees and a corporate culture that encourages engagement and motivation. At Sectra, we are proud that our customers time and time...
PR Newswire
08/03/2024
Altri  Comunicati